Published in Psychopharmacology (Berl) on October 17, 2008
Single units in the medial prefrontal cortex with anxiety-related firing patterns are preferentially influenced by ventral hippocampal activity. Neuron (2011) 1.61
Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study. Psychopharmacology (Berl) (2010) 1.29
Corticotropin-releasing factor in the norepinephrine nucleus, locus coeruleus, facilitates behavioral flexibility. Neuropsychopharmacology (2011) 1.20
Pharmacological enhancement of memory and executive functioning in laboratory animals. Neuropsychopharmacology (2010) 1.10
Methamphetamine self-administration produces attentional set-shifting deficits and alters prefrontal cortical neurophysiology in rats. Biol Psychiatry (2010) 1.08
Delayed procedural learning in α7-nicotinic acetylcholine receptor knockout mice. Genes Brain Behav (2011) 1.08
Prefrontal cortical contributions during discriminative fear conditioning, extinction, and spontaneous recovery in rats. Exp Brain Res (2010) 0.94
A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response. J Clin Psychopharmacol (2010) 0.94
Gonadectomy and hormone replacement affects in vivo basal extracellular dopamine levels in the prefrontal cortex but not motor cortex of adult male rats. Cereb Cortex (2010) 0.92
Transient inactivation of the neonatal ventral hippocampus impairs attentional set-shifting behavior: reversal with an α7 nicotinic agonist. Neuropsychopharmacology (2012) 0.89
Evaluation of the clinical efficacy of asenapine in schizophrenia. Expert Opin Pharmacother (2010) 0.86
Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology (Berl) (2009) 0.85
Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity. Neuropharmacology (2013) 0.84
Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism. Psychopharmacology (Berl) (2010) 0.84
Modeling deficits in attention, inhibition, and flexibility in HAND. J Neuroimmune Pharmacol (2014) 0.81
Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology (Berl) (2009) 0.80
Fos expression in the brains of rats performing an attentional set-shifting task. Neuroscience (2010) 0.78
Asenapine sensitization from adolescence to adulthood and its potential molecular basis. Behav Brain Res (2014) 0.76
What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry (1996) 11.03
Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"? Schizophr Bull (2000) 9.62
Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry (1987) 8.81
Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci (2000) 5.30
Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry (1986) 4.34
Medicine. What are the right targets for psychopharmacology? Science (2003) 2.86
Primate analogue of the Wisconsin Card Sorting Test: effects of excitotoxic lesions of the prefrontal cortex in the marmoset. Behav Neurosci (1996) 2.27
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol (2008) 2.16
Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease. Brain (1993) 2.07
Cognitive inflexibility and pre-frontal dysfunction in schizophrenia and mania. Br J Psychiatry (1990) 1.76
Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res (1999) 1.72
Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry (2007) 1.72
Prelimbic/infralimbic inactivation impairs memory for multiple task switches, but not flexible selection of familiar tasks. J Neurosci (2007) 1.40
West London first-episode study of schizophrenia. Clinical correlates of duration of untreated psychosis. Br J Psychiatry (2000) 1.39
Neuropsychological evidence for frontostriatal dysfunction in schizophrenia. Psychol Med (1995) 1.34
A meta-analytic review of the sensitivity of the Wisconsin Card Sorting Test to frontal and lateralized frontal brain damage. Neuropsychology (2003) 1.31
Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. Neuropsychopharmacology (1996) 1.26
Intra-dimensional/extra-dimensional set-shifting performance in schizophrenia: impact of distractors. Schizophr Res (2006) 1.21
Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. Wisconsin Card Sorting Test. Continuous Performance Test. J Psychiatr Res (2001) 1.18
Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biol Psychiatry (1993) 1.18
The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia. Neuropsychopharmacology (2000) 1.14
A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients. Schizophr Res (2005) 1.14
PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci (2005) 1.13
Factors of the Wisconsin Card Sorting Test as measures of frontal-lobe function in schizophrenia and in chronic alcoholism. Psychiatry Res (1993) 1.12
Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) (2007) 1.11
Sensitization to amphetamine, but not PCP, impairs attentional set shifting: reversal by a D1 receptor agonist injected into the medial prefrontal cortex. Psychopharmacology (Berl) (2005) 1.07
Stability of set-shifting and planning abilities in patients with schizophrenia. Psychiatry Res (2004) 0.97
Perirhinal cortex damage and anterograde object-recognition in rats after long retention intervals. Behav Brain Res (2007) 0.97
5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats. Psychopharmacology (Berl) (2005) 0.96
Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology (2007) 0.93
Acute delta9-tetrahydrocannabinol-induced deficits in reversal learning: neural correlates of affective inflexibility. Neuropsychopharmacology (2005) 0.92
Sulpiride alleviates the attentional impairments of rats with medial prefrontal cortex lesions. Behav Brain Res (2003) 0.91
Stimulus-bound perseveration after frontal ablations in marmosets. Neuroscience (1993) 0.90
Wisconsin Card Sorting Test performance in schizophrenia: the role of working memory. Schizophr Res (2003) 0.90
Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology (2008) 0.87
Local and downstream effects of excitotoxic lesions in the rat medial prefrontal cortex on In vivo 1H-MRS signals. Neuropsychopharmacology (2000) 0.85
Cognition in schizophrenia: from basic science to clinical treatment. Psychopharmacology (Berl) (2003) 0.84
On the nature of Wisconsin Card Sorting Test performance in schizophrenia. Psychiatry Res (1996) 0.83
Performance on the Wisconsin Card Sorting Test in schizophrenia: perseveration in clinical subtypes. Psychiatry Res (1996) 0.81
A review of the effects of modafinil on cognition in schizophrenia. Schizophr Bull (2007) 0.80
Neurocognitive and social functioning in schizophrenia and other diagnoses. Schizophr Res (2001) 0.77
The VPAC(2) receptor is essential for circadian function in the mouse suprachiasmatic nuclei. Cell (2002) 3.29
Orbital prefrontal cortex mediates reversal learning and not attentional set shifting in the rat. Behav Brain Res (2003) 3.25
Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India. Ann Clin Microbiol Antimicrob (2007) 3.07
Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther (2009) 1.67
Vagal nerve stimulation: a review of its applications and potential mechanisms that mediate its clinical effects. Neurosci Biobehav Rev (2005) 1.63
Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice. Eur Neuropsychopharmacol (2006) 1.62
Refinement of the use of food and fluid control as motivational tools for macaques used in behavioural neuroscience research: report of a Working Group of the NC3Rs. J Neurosci Methods (2010) 1.61
The mouse VPAC2 receptor confers suprachiasmatic nuclei cellular rhythmicity and responsiveness to vasoactive intestinal polypeptide in vitro. Eur J Neurosci (2003) 1.56
Nicotine improves sustained attention in mice: evidence for involvement of the alpha7 nicotinic acetylcholine receptor. Neuropsychopharmacology (2004) 1.46
Lesions of the dorsal noradrenergic bundle impair attentional set-shifting in the rat. Eur J Neurosci (2007) 1.32
The 5-choice continuous performance test: evidence for a translational test of vigilance for mice. PLoS One (2009) 1.20
Inhibition of thalamic excitability by 4,5,6,7-tetrahydroisoxazolo[4,5-c]pyridine-3-ol: a selective role for delta-GABA(A) receptors. Eur J Neurosci (2009) 1.18
Double dissociation of social and environmental stimulation on spatial learning and reversal learning in rats. Behav Brain Res (2004) 1.15
Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) (2007) 1.11
Lesions of the basal forebrain impair reversal learning but not shifting of attentional set in rats. Behav Brain Res (2007) 1.06
The effect of striatal dopamine depletion and the adenosine A2A antagonist KW-6002 on reversal learning in rats. Neurobiol Learn Mem (2007) 1.03
Lesions of the orbital prefrontal cortex impair the formation of attentional set in rats. Eur J Neurosci (2012) 1.03
The odour span task: a novel paradigm for assessing working memory in mice. Neuropharmacology (2006) 1.02
Difficulty overcoming learned non-reward during reversal learning in rats with ibotenic acid lesions of orbital prefrontal cortex. Ann N Y Acad Sci (2007) 1.01
Recordings from the rat locus coeruleus during acute vagal nerve stimulation in the anaesthetised rat. Neurosci Lett (2005) 1.00
Glycine transporter-1 blockade leads to persistently reduced relapse-like alcohol drinking in rats. Biol Psychiatry (2010) 0.99
5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats. Psychopharmacology (Berl) (2005) 0.96
Measuring the construct of executive control in schizophrenia: defining and validating translational animal paradigms for discovery research. Neurosci Biobehav Rev (2012) 0.95
Discrimination reversal and attentional sets in zebrafish (Danio rerio). Behav Brain Res (2012) 0.93
Metabotropic and ionotropic glutamate receptors as neurobiological targets in anxiety and stress-related disorders: focus on pharmacology and preclinical translational models. Pharmacol Biochem Behav (2011) 0.91
The thalamic reticular nucleus: more than a sensory nucleus? Neuroscientist (2002) 0.90
Acute oral dexamethasone administration reduces levels of orphan GPCR glucocorticoid-induced receptor (GIR) mRNA in rodent brain: potential role in HPA-axis function. Brain Res Mol Brain Res (2003) 0.89
Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology (2008) 0.87
The effect of the adenosine A(2A) antagonist KW-6002 on motor and motivational processes in the rat. Psychopharmacology (Berl) (2005) 0.86
Asenapine effects in animal models of psychosis and cognitive function. Psychopharmacology (Berl) (2009) 0.85
Electrophysiological characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and D(2) receptors in the rat brain. Eur Neuropsychopharmacol (2008) 0.85
Evaluation of an operant successive negative contrast task as a method to study affective state in rodents. Behav Brain Res (2012) 0.84
Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism. Psychopharmacology (Berl) (2010) 0.84
Differential regional and dose-related effects of asenapine on dopamine receptor subtypes. Psychopharmacology (Berl) (2008) 0.84
Lesions of the dorsomedial striatum impair formation of attentional set in rats. Neuropharmacology (2013) 0.83
Multi- and single-target agents for major psychiatric diseases: therapeutic opportunities and challenges. Curr Opin Investig Drugs (2008) 0.83
The effects of DISC1 risk variants on brain activation in controls, patients with bipolar disorder and patients with schizophrenia. Psychiatry Res (2011) 0.83
Effects of asenapine on prefrontal N-methyl-D-aspartate receptor-mediated transmission: involvement of dopamine D1 receptors. Synapse (2010) 0.82
Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration. Neuropharmacology (2011) 0.82
The ampakine, Org 26576, bolsters early spatial reference learning and retrieval in the Morris water maze: a subchronic, dose-ranging study in rats. Behav Pharmacol (2009) 0.82
Phencyclidine (PCP)-induced disruption in cognitive performance is gender-specific and associated with a reduction in brain-derived neurotrophic factor (BDNF) in specific regions of the female rat brain. J Mol Neurosci (2010) 0.82
The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action. Pharmacol Ther (2010) 0.81
Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors. Int J Neuropsychopharmacol (2009) 0.80
Validation of a rat in vivo [(3)H]M100907 binding assay to determine a translatable measure of 5-HT(2A) receptor occupancy. Eur J Pharmacol (2008) 0.80
Translational PK-PD modelling of molecular target modulation for the AMPA receptor positive allosteric modulator Org 26576. Psychopharmacology (Berl) (2011) 0.80
Attenuation of chronic mild stress-induced 'anhedonia' by asenapine is not associated with a 'hedonic' profile in intracranial self-stimulation. J Psychopharmacol (2010) 0.80
Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat. Behav Brain Res (2010) 0.80
Chronic treatment with AMPA receptor potentiator Org 26576 increases neuronal cell proliferation and survival in adult rodent hippocampus. Psychopharmacology (Berl) (2009) 0.80
Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology (Berl) (2009) 0.80
Attention to visual, but not tactile, properties of a stimulus results in activation of FOS protein in the visual thalamic reticular nucleus of rats. Behav Brain Res (2010) 0.80
Subchronic effects of phencyclidine on dopamine and serotonin receptors: implications for schizophrenia. J Mol Neurosci (2009) 0.79
Characterization of a novel and selective V1B receptor antagonist. Prog Brain Res (2008) 0.79
Regionally selective and dose-dependent effects of the ampakines Org 26576 and Org 24448 on local cerebral glucose utilisation in the mouse as assessed by 14C-2-deoxyglucose autoradiography. Neuropharmacology (2005) 0.79
SleepAp: an automated obstructive sleep apnoea screening application for smartphones. IEEE J Biomed Health Inform (2015) 0.79
Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain. Synapse (2009) 0.78
A translational approach to evaluate the efficacy and safety of the novel AMPA receptor positive allosteric modulator org 26576 in adult attention-deficit/hyperactivity disorder. Biol Psychiatry (2012) 0.77
Tacrine improves reversal learning in older rats. Neuropharmacology (2013) 0.77
Asenapine maleate: a new drug for the treatment of schizophrenia and bipolar mania. Drugs Today (Barc) (2009) 0.77
Amphetamine and the adenosine A(2A) antagonist KW-6002 enhance the effects of conditional temporal probability of a stimulus in rats. Behav Neurosci (2007) 0.76
The AMPA receptor potentiator Org 26576 modulates stress-induced transcription of BDNF isoforms in rat hippocampus. Pharmacol Res (2011) 0.76
Differential effects of AMPA receptor potentiators and glycine reuptake inhibitors on antipsychotic efficacy and prefrontal glutamatergic transmission. Psychopharmacology (Berl) (2011) 0.76
The α2C-adrenoceptor antagonist, ORM-10921, exerts antidepressant-like effects in the Flinders Sensitive Line rat. Behav Pharmacol (2016) 0.75
Compatibility of electroanatomical mapping systems with a concurrent percutaneous axial flow ventricular assist device. J Cardiovasc Electrophysiol (2014) 0.75